Literature DB >> 24932027

Classification, imaging, biopsy and staging of osteosarcoma.

Zile Singh Kundu1.   

Abstract

Osteosarcoma is the most common primary osseous malignancy excluding malignant neoplasms of marrow origin (myeloma, lymphoma and leukemia) and accounts for approximately 20% of bone cancers. It predominantly affects patients younger than 20 years and mainly occurs in the long bones of the extremities, the most common being the metaphyseal area around the knee. These are classified as primary (central or surface) and secondary osteosarcomas arising in preexisting conditions. The conventional plain radiograph is the best for probable diagnosis as it describes features like sun burst appearance, Codman's triangle, new bone formation in soft tissues along with permeative pattern of destruction of the bone and other characteristics for specific subtypes of osteosarcomas. X-ray chest can detect metastasis in the lungs, but computerized tomography (CT) scan of the thorax is more helpful. Magnetic resonance imaging (MRI) of the lesion delineates its extent into the soft tissues, the medullary canal, the joint, skip lesions and the proximity of the tumor to the neurovascular structures. Tc99 bone scan detects the osseous metastases. Positron Emission Tomography (PET) is used for metastatic workup and/or local recurrence after resection. The role of biochemical markers like alkaline phosphatase and lactate dehydrogenase is pertinent for prognosis and treatment response. The biopsy confirms the diagnosis and reveals the grade of the tumor. Enneking system for staging malignant musculoskeletal tumors and American Joint Committee on Cancer (AJCC) staging systems are most commonly used for extremity sarcomas.

Entities:  

Keywords:  Enneking staging; Osteosarcoma; biopsy; imaging

Year:  2014        PMID: 24932027      PMCID: PMC4052020          DOI: 10.4103/0019-5413.132491

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.251


INTRODUCTION

Osteosarcoma is defined as the primary malignant mesenchymal bone tumor where the malignant tumor cells directly form the osteoid or bone or both.123456789101112 Demonstration of osteoid directly formed by the malignant cells in histopathology is essential for making the diagnosis of osteosarcoma.23 Although the exact cause of osteosarcoma is still unknown, defects in RB and p53 genes play an important role in the process. Patients with germline mutations in RB have approximately 1000-fold increased risk of osteosarcoma and similarly patients with Li-Fraumeni syndrome (germline p53 mutation) also have greatly elevated incidence of this tumor. Abnormalities in INK4a, which encodes p16 (a cell cycle regulator) and p14 (which aids and abets p53 function) are also seen. It is noteworthy that osteosarcoma occurs more commonly at sites of bone growth, presumably because proliferation makes osteoblastic cells to acquire mutations that could lead to transformation.1 Radiation too has been implicated in causation.12 The risk of developing postradiation osteosarcoma correlates with radiation dose and use of electrophilic chemotherapeutic agents.131415 An etiological relationship has not been proven in prosthesis and metal hardware associated osteosarcomas.16

Classification

Osteosarcomas are classified as primary and secondary. Primary are further sub-typed as intramedullry/central and surface osteosarcomas as per World Health Organization classification2 [Box 1].
Box 1

Classification of osteosarcoma

Classification of osteosarcoma

RADIOLOGICAL INVESTIGATIONS

Common sites of involvement of osteosarcoma are the metaphyseal areas (91%) of long bones of the extremities with its occurrence in (descending order) lower end of femur, upper end of tibia, upper end of humerus and upper end of femur. It can uncommonly occur in the diaphysis (9%) [Figure 1a]. Almost 50% of osteosarcomas occur around the knee. Involvement of nonlong bones like jaw (gnathic), pelvis, scapula, spine, and skull increases with age. Involvement beyond the wrist and ankle (acral sites) is extremely rare.2
Figure 1

(a) X-ray anteroposterior and lateral views of proximal tibia and knee joint showing diaphyseal osteosarcoma of tibia with sclerosis (arrow), cortical destruction on posteromedial side (arrow heads) and new bone formation in the soft tissues (b) x-ray distal end of femur (anteroposterior and lateral views) showing sclerosis/radio-opacity in sclerosing osteosarcoma

(a) X-ray anteroposterior and lateral views of proximal tibia and knee joint showing diaphyseal osteosarcoma of tibia with sclerosis (arrow), cortical destruction on posteromedial side (arrow heads) and new bone formation in the soft tissues (b) x-ray distal end of femur (anteroposterior and lateral views) showing sclerosis/radio-opacity in sclerosing osteosarcoma

Plain X-ray

The characteristic radiological features are sun-burst appearance, periosteal lifting with formation of Codman's triangle [Figure 2], new bone formation in the soft tissues along with permeative pattern of destruction of bone and other features for specific types of osteosarcoma.281718 Osteolysis and expansion in the telangiectatic variety [Figure 3] of bone is observed while more of osteoblastic appearance is seen in the sclerosing type of osteosarcoma [Figure 1b]. The physis (growth plate) may, but not always, act as a barrier to tumor growth. Surface osteosarcomas have typical appearances [Figure 4]. After chemotherapy the tumor becomes well defined, capsulated, and more mineralized [Figure 5]. X-ray chest can detect metastasis in form of cannon ball appearance or nodules in the lungs [Figure 6a], but it is less sensitive than computerized tomography (CT) scan of the thorax [Figure 6b] for early detection of small sub-centimal nodules.19
Figure 2

X-ray of humerus anteroposterior view showing osteosarcoma of the proximal humerus- typical sun burst or sun ray appearance, new bone formation in soft tissues, and Codman's triangles (arrows)

Figure 3

Telangiectatic type of osteosarcoma of the proximal tibia: (a) X-ray anteroposterior and lateral views showing lysis and expansion (b) MRI showing fluid levels

Figure 4

X-ray of knee joint anteroposterior views showing surface osteosarcoma: (a) parosteal (b) periosteal. See the under lying cortex is visibly intact in ‘a’ and lifting of periosteum in ‘b’ (red arrow). However, both are on the surface of the bone

Figure 5

X-ray anteroposterior and lateral views showing that after chemotherapy the tumor becomes well defined with better capsulation: (a) before chemotherapy and (b) after chemotherapy

Figure 6

(a) Plain X-ray chest of a patient of osteosarcoma showing multiple metastatic lung nodules (b) CT scan (axial section) demonstrating multiple metastases in both lungs (c) Tc-99m bone scan of osteosarcoma in the proximal humerus with hot spot at this site and in spine, ribs and a focus in the skull bone

X-ray of humerus anteroposterior view showing osteosarcoma of the proximal humerus- typical sun burst or sun ray appearance, new bone formation in soft tissues, and Codman's triangles (arrows) Telangiectatic type of osteosarcoma of the proximal tibia: (a) X-ray anteroposterior and lateral views showing lysis and expansion (b) MRI showing fluid levels X-ray of knee joint anteroposterior views showing surface osteosarcoma: (a) parosteal (b) periosteal. See the under lying cortex is visibly intact in ‘a’ and lifting of periosteum in ‘b’ (red arrow). However, both are on the surface of the bone X-ray anteroposterior and lateral views showing that after chemotherapy the tumor becomes well defined with better capsulation: (a) before chemotherapy and (b) after chemotherapy (a) Plain X-ray chest of a patient of osteosarcoma showing multiple metastatic lung nodules (b) CT scan (axial section) demonstrating multiple metastases in both lungs (c) Tc-99m bone scan of osteosarcoma in the proximal humerus with hot spot at this site and in spine, ribs and a focus in the skull bone

Computerized tomography scan

CT scan delineates the bony anatomy/architecture like cortical integrity more clearly and picks up pathological fracture and is helpful in assessing ossification and calcification (chondroid component) more accurately.2021 However, the soft tissue component and medullary extent is best defined by an MRI.222324

Magnetic resonance imaging

MRI is the most accurate tool for determining the limits of tumor within and outside the bone.7222324 MRI should include the whole of the involved bone with one joint above and below so that skip lesions are not missed in the same bone and across the joint. MRI accurately and precisely delineates (1) extent of the tumor into the soft tissues and the medullary canal, (2) involvement of joint, (3) crossing of the lesion through and/or around the growth plate, (4) any skip lesion in the same bone and across the joint in other bone, (5) proximity and/or encasement of the neurovascular bundle by the tumor [Figure 7]. Recently, even the response of chemotherapy is being judged by MRI as the neo-angiogenesis decreases with chemotherapy, necrosis occurs, and the tumor shrinks with better capsulation. This is done by performing a contrast enhancement and diffusion MRI.2526 MRI is also being coupled with Positron Emission Tomography for detection of the systemic involvement by the tumor, local recurrence, and metastasis after treatment. In view of the nonspecific findings of an MRI, it should always be correlated with the patient's x-ray.
Figure 7

Osteosarcoma in the distal end of femur: (a) X-ray thigh with knee anteroposterior view showing big soft tissue component on the medial side; (b) MRI-coronal section showing the medullary extent (arrow); (c) MRI-axial section showing the proximity of the popliteal vessels

Osteosarcoma in the distal end of femur: (a) X-ray thigh with knee anteroposterior view showing big soft tissue component on the medial side; (b) MRI-coronal section showing the medullary extent (arrow); (c) MRI-axial section showing the proximity of the popliteal vessels

Radionuclide bone scan

Tc99 methylenediphosphonate (Tc99 MDP) bone scan is the most commonly used investigation for detecting osseous metastasis [Figure 6c]. It is performed by injecting 20 mCi of isotope intravenously and taking images at different intervals, in three phases: (1) the flow phase, (2) the immediate or equilibrium phase, and (3) the delayed phase. The flow phase demonstrates blood flow just like radionuclide angiogram; the equilibrium phase shows the reactive vascular flow and the distribution in the intercellular spaces, and the delayed phase is after 2-4 hours when the radionuclide is excreted in the urine except in the areas of the osteoblastic activities. This radio-isotope has special predilection to the sites of increased osteoblastic activity and highly vascular areas like the sites of metastasis in sarcomas. It is most easily available and cost-effective investigation for detecting bony metastasis in osteosarcoma.27

Positron emission tomography

Positron Emission Tomography (PET), which picks up metabolic activity is evolving with tremendous potential in oncology.28293031323334 Further combining the images of ‘form’ i.e. the anatomical structure provided by CT and MRI and those of ‘function’ i.e. metabolic or biochemical activity, provided by PET can be precisely aligned or correlated. MRI combined with PET facility reduces radiation exposure when compared to a CT. PET is utilized in: (1) selecting the region of a tumor most likely to yield diagnostic information for biopsy, (2) staging known malignancies, (3) monitoring the effect of therapy, (4) to establish the cause of suspected recurrence seen on other imaging modalities. It differentiates between fibrosis and recurrent tumor (5) detecting tumor recurrence, especially in the presence of elevated levels of tumor markers, (6) differentiating benign from malignant lesions, (7) searching for an unknown primary tumor with metastasis of unknown origin, (8) guiding radiation therapy planning.33 The main drawback is the difficulty and cost of producing and transporting the radiopharmaceuticals used for PET imaging, which are usually extremely short-lived. The half life of radioactive fluorine18 used to trace glucose metabolism (using fluorodeoxyglucose, FDG) is 2 hours only. Its production requires a very expensive cyclotron as well as a production line for the radiopharmaceuticals. It can give false negative and positive results and is still considered the investigation under continuing research.3334

Biochemical markers

The role of biochemical markers like serum alkaline phosphatase (ALP) and lactate dehydrogenases (LDH) for diagnosis, prognosis and response to treatment is pertinent to mention. Levels of alkaline phosphatase are elevated in osteosarcoma due to increased osteoblastic activity. Higher levels are associated with heavy tumor burden and poor prognosis. The response of therapy can be monitored with the levels of these enzymes. High levels after treatment may persist with residual disease or recurrence and in the presence of metastasis.8

Biopsy

Biopsy should be performed after complete history, clinical examination and imaging. It confirms the diagnosis, reveals specific type and furnishes the grade of the tumor. It is performed by either an open (incisional) or a closed method. Closed biopsy is performed as fine needle aspiration cytology (FNAC) and core needle biopsy.7 Open or incisional biopsy is performed through a small incision [Figure 8] and has the major advantage of obtaining adequate amount of sample for histopathology as well as for ancillary studies like immunohistocytochemistry (IHC) and genetic studies. But it takes more time and requires operation theatre set-up with instruments. There are more chances of contamination of normal soft tissue by tumor cells through an impending hematoma and also other complications like infection and wound problems posing greater morbidity. Further, there is more cost to the patient as it may require short stay in the hospital. However, if performed meticulously and properly, the complications can be reduced markedly almost comparable to those of a core needle biopsy.7 Percutaneous core needle biopsy has now evolved as a better, safe and accurate method for diagnosing of bone tumors. It is performed through a small stab using the Jamshidi needle and taking multiple cores from the representative part of the tumor [Figure 9]. It is less extensive and less time consuming outpatient procedure performed safely and quickly under local anesthesia and is cost effective. There is minimal soft tissue trauma with less contamination of normal tissue by the tumor cells around the tract of the needle which is easily excisable during the limb salvage surgery. It is very suitable for deep and difficult areas like the pelvis and spine.56 The efficacy and accuracy can be further increased by performing this under image guidance i.e. under CT scan, MRI or ultrasonography. The recent literature advocates core needle biopsy as it provides adequate amount of sample for the diagnosis and the ancillary studies, and has less number of complications.3536373839404142434445464748
Figure 8

Open biopsies taken through small two cm incisions without making different planes. The incisions were placed such that these can be well resected with definitive resection of the tumor

Figure 9

Core needle biopsy: (a) Jamshidi needle with trochar and stylet. (b) Biopsy being taken through stab incision. (c) Five good cores taken

Open biopsies taken through small two cm incisions without making different planes. The incisions were placed such that these can be well resected with definitive resection of the tumor Core needle biopsy: (a) Jamshidi needle with trochar and stylet. (b) Biopsy being taken through stab incision. (c) Five good cores taken FNAC does not have much role in majority of bone and soft tissue sarcomas as only few cells are inadequate for making a specific diagnosis and conducting ancillary studies. Ideally one should not start oncological treatment on the basis of a cytological diagnosis.7 Whether performed open or close, there are set principles for biopsy of musculoskeletal tumors which holds true for osteosarcoma too. Where, who, and how the biopsy should be performed are important issues. The biopsy is such an instrumental step that if not performed properly, the end result of definitive treatment can be affected significantly. We have noticed poorly performed biopsies in patients referred from periphery by nonspecialized general orthopedic surgeons and by un-experienced junior surgeons even at our institute. The incisions for biopsy were wrongly placed [Figure 10], patients had infection at the biopsy site due to big hematoma, and there were nondiagnostic samples due to inadequate material taken from nonrepresentative areas of the tumor. Due to these improper biopsies, the optimal treatment plan required alteration. The importance of biopsy has been well emphasized in literature by Mankin et al. who observed that because of wrong biopsies unnecessary amputations were performed in 4.5% of patients and the prognosis and outcome was altered in 8.5% of their patients. They found 18.2% major errors in diagnosis and 10.3% of biopsies being nonrepresentative. It has been emphasized that ideally the biopsy should be performed at the center where the definitive treatment of the tumor is to be performed under the guidance of a welltrained oncologist, taking all precautions, and following the basic principles.4647484950 If the principles are followed properly the final outcome will obviously be better with lesser complications. This will prevent the repetition of biopsy and the treatment delay with reduction of overall cost42 [Box 2].
Figure 10

Poorly performed biopsies: (a) Avoid transverse incision in the extremity because this is difficult to excise with definitive resection. (b) Never biopsy through buttock as this is the flap for the coverage in the hind quarter amputation if required. (c) Never biopsy through rectus femoris; very important for knee extension (d) Poor biopsy: Long incision and widely placed sutures marks will require excision of wide area of skin and under lying tissues if salvage surgery is contemplated and the wound closure may be compromised

Box 2

Principles of biopsy

Poorly performed biopsies: (a) Avoid transverse incision in the extremity because this is difficult to excise with definitive resection. (b) Never biopsy through buttock as this is the flap for the coverage in the hind quarter amputation if required. (c) Never biopsy through rectus femoris; very important for knee extension (d) Poor biopsy: Long incision and widely placed sutures marks will require excision of wide area of skin and under lying tissues if salvage surgery is contemplated and the wound closure may be compromised Principles of biopsy

Staging

The common staging systems for malignant bone tumors are: Enneking system for staging malignant musculoskeletal tumors and the American Joint Committee on Cancer (AJCC) System for staging bone sarcomas.6 The former is based on the histological grade of the tumor, its local extent and the presence or absence of metastasis [Table 1]. Low grade lesions are stage-I, are well differentiated, have few mitoses and exhibit only moderate cytological atypia with low risk of metastasis (less than 25%). High grade lesions are stage-II are poorly differentiated, have high mitotic rate, and high cell to matrix ratio. On the basis of the involvement of the anatomical compartment (as determined by the natural anatomical barriers to tumor growth like cortical bone, articular cartilage, fascial septa, or joint capsules) these are further sub-divided as A and B. Stage–IA and IIA are contained in well defined compartment (intracompartmental) and stage–IB and IIB lesions extend beyond the compartment of origin (extracompartmental). Stage –III are lesions with metastasis (lymph node or distant) regardless of the size and grade.27
Table 1

Enneking system for staging malignant musculoskeletal tumors

Enneking system for staging malignant musculoskeletal tumors The AJCC system for bone sarcomas is based on tumor grade, size, presence, and location of metastases [Table 2]. Stage-I tumors are low grade and stage-II are high grade, which are subdivided based on tumor size. Stages I-A and II-A are 8 cm or less in their greatest linear measurement; stage I-B and II-B are larger than 8 cm. Stage III tumors have “skip metastases”, which are defined as discontinuous lesions within the same bone. Stage IV-A involves pulmonary metastases, whereas Stage IV-B involves nonpulmonary metastases. The stage IV is subdivided because patients with nonpulmonary metastases from osteosarcoma have worse prognosis than those with only pulmonary metastases.75152, 53
Table 2

American joint committee on cancer system for staging bone sarcomas

American joint committee on cancer system for staging bone sarcomas

CONCLUSION

The plain radiograph provides the best clue to the diagnosis and MRI the local extent. Thorax CT scan and Tc99 bone scan are used for the detection of lung and bony metastasis respectively. The biopsy confirms the diagnosis and reveals the grade of the lesion. The basic principles of biopsy should be followed precisely and meticulously. After clinical, radiological and the histopathological examinations the tumor can be staged adequately [Box 3]. It is pertinent to mention that the patient should be immediately referred to the treating specialist centre for early diagnosis and treatment as this can make limb salvage possible in large number of patients. The urgent need of the MDT (multidisciplinay team) for the better out come in all musculoskeletal sarcomas can not be over-emphasised. However, the biological behavior of osteosarcoma is yet to be fully understood.
Box 3

Algorithm for staging osteosarcoma in distal femur

Algorithm for staging osteosarcoma in distal femur
  39 in total

1.  Diagnosis of orthopaedic lesions by aspiration biopsy; results of 1,061 punctures.

Authors:  C E OTTOLENGHI
Journal:  J Bone Joint Surg Am       Date:  1955-06       Impact factor: 5.284

Review 2.  Malignant tumors at the site of total hip prosthesis. Analytic review of 46 cases.

Authors:  Tuomo Visuri; Pekka Pulkkinen; Pekka Paavolainen
Journal:  J Arthroplasty       Date:  2006-04       Impact factor: 4.757

3.  Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors.

Authors:  James S Jelinek; Mark D Murphey; James A Welker; Robert M Henshaw; Mark J Kransdorf; Barry M Shmookler; Martin M Malawer
Journal:  Radiology       Date:  2002-06       Impact factor: 11.105

4.  Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  Markus Uhl; Ulrich Saueressig; Miriam van Buiren; Udo Kontny; Charlotte Niemeyer; Gabriele Köhler; Kamil Ilyasov; Mathias Langer
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

5.  Closed biopsy of musculoskeletal lesions.

Authors:  T M Moore; M H Meyers; M J Patzakis; R Terry; J P Harvey
Journal:  J Bone Joint Surg Am       Date:  1979-04       Impact factor: 5.284

6.  Bone sarcomas linked to radiotherapy and chemotherapy in children.

Authors:  M A Tucker; G J D'Angio; J D Boice; L C Strong; F P Li; M Stovall; B J Stone; D M Green; F Lombardi; W Newton
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

7.  Osteosarcoma: chemotherapy-induced changes at MR imaging.

Authors:  H C Holscher; J L Bloem; D Vanel; J Hermans; M A Nooy; A H Taminiau; M Henry-Amar
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

8.  Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients.

Authors:  A G Huvos; H Q Woodard; W G Cahan; N L Higinbotham; F W Stewart; A Butler; S S Bretsky
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

9.  Magnetic resonance imaging of primary tumours and tumour-like lesions of bone.

Authors:  K Bohndorf; M Reiser; B Lochner; W Féaux de Lacroix; W Steinbrich
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

10.  The use of computed tomography to distinguish osteochondroma and chondrosarcoma.

Authors:  P J Kenney; L A Gilula; W A Murphy
Journal:  Radiology       Date:  1981-04       Impact factor: 11.105

View more
  39 in total

Review 1.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

Review 2.  A review of imaging of surface sarcomas of bone.

Authors:  Kelly Harper; Paul Sathiadoss; Asif Saifuddin; Adnan Sheikh
Journal:  Skeletal Radiol       Date:  2020-07-17       Impact factor: 2.199

3.  Gene function analysis in osteosarcoma based on microarray gene expression profiling.

Authors:  Liang Zhao; Jinghua Zhang; Hongyu Tan; Weidong Wang; Yilin Liu; Ruipeng Song; Limin Wang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

Review 5.  Role of osteopontin in osteosarcoma.

Authors:  Yu-Sheng Li; Zhen-Han Deng; Chao Zeng; Guang-Hua Lei
Journal:  Med Oncol       Date:  2014-12-17       Impact factor: 3.064

6.  Accuracy of X-Ray and Magnetic Resonance Imaging in Defining the Tumor Margin in Primary Bone Sarcoma.

Authors:  Theodore H Katz; Obada H Hasan; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2021-12

7.  The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma.

Authors:  James R Barnett; Panagiotis Gikas; Craig Gerrand; Tim Wr Briggs; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2020-01-04       Impact factor: 2.199

8.  Automated Classification of Osteosarcoma and Benign Tumors using RNA-seq and Plain X-ray.

Authors:  Olivia Alge; Lu Lu; Zhi Li; Yingqi Hua; Jonathan Gryak; Kayvan Najarian
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2020-07

Review 9.  Research models and mesenchymal/epithelial plasticity of osteosarcoma.

Authors:  Xiaobin Yu; Jason T Yustein; Jianming Xu
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

10.  What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?

Authors:  Aayush Aryal; Venkatesan Sampath Kumar; Shamim Ahmed Shamim; Shivanand Gamanagatti; Shah Alam Khan
Journal:  Clin Orthop Relat Res       Date:  2021-08-01       Impact factor: 4.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.